Sandbox: sadaf: Difference between revisions
Jump to navigation
Jump to search
Line 5: | Line 5: | ||
! rowspan="5" |Category | ! rowspan="5" |Category | ||
! colspan="2" rowspan="5" |Condition | ! colspan="2" rowspan="5" |Condition | ||
! rowspan="5" |Mechanism | |||
! | |||
! | |||
! | |||
! rowspan="5" |Age range | |||
! | ! | ||
! colspan="9" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations | ! colspan="9" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations | ||
! | ! | ||
! colspan=" | ! colspan="10" rowspan="2" |Para−clinical findings | ||
! colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ! colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ||
|- | |- | ||
! | |||
! | |||
! | |||
! | ! | ||
! colspan="7" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms | ! colspan="7" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms | ||
Line 19: | Line 27: | ||
! | ! | ||
! | ! | ||
! colspan=" | ! | ||
! | |||
! | |||
! colspan="9" |Lab Findings | |||
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ||
|- | |- | ||
! | |||
! | |||
! | |||
! | ! | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Severity | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Severity | ||
Line 31: | Line 45: | ||
! rowspan="2" | | ! rowspan="2" | | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly | ||
! | ! | ||
! | ! colspan="3" |CBC | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam | ||
! | ! | ||
! | ! | ||
Line 41: | Line 55: | ||
! | ! | ||
|- | |- | ||
! | !Myelosuppression | ||
!Platelet destruction in bloodstream | |||
!Platelet destruction in spleen/liver | |||
!History | |||
! | ! | ||
!Plt | |||
!HB | |||
!WBC | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |BT | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ||
|- | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ||
! align="center" style="background:#DCDCDC;" + |Gestational thrombocytopenia | ! align="center" style="background:#DCDCDC;" + |Gestational thrombocytopenia | ||
! | ! | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 61: | Line 86: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 73: | Line 100: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! | |||
! align="center" style="background:#DCDCDC;" + |Chronic liver disease | ! align="center" style="background:#DCDCDC;" + |Chronic liver disease | ||
! | ! | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 85: | Line 118: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 97: | Line 132: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! | |||
! align="center" style="background:#DCDCDC;" + |portal hypertension | ! align="center" style="background:#DCDCDC;" + |portal hypertension | ||
! | ! | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 109: | Line 150: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 121: | Line 164: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! | |||
! align="center" style="background:#DCDCDC;" + |Hypersplenism | ! align="center" style="background:#DCDCDC;" + |Hypersplenism | ||
! | ! | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 133: | Line 182: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 145: | Line 196: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! | |||
! align="center" style="background:#DCDCDC;" + |Immune thrombocytopenia | ! align="center" style="background:#DCDCDC;" + |Immune thrombocytopenia | ||
! | ! | ||
|Antibody-mediated platelet destruction | |Antibody-mediated platelet destruction | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + |Moderate to severe | | align="center" style="background:#F5F5F5;" + |Moderate to severe | ||
| align="center" style="background:#F5F5F5;" + | - | | align="center" style="background:#F5F5F5;" + | - | ||
Line 157: | Line 214: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 169: | Line 228: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! | |||
! rowspan="7" align="center" style="background:#DCDCDC;" + |Congenital platelet disorders | ! rowspan="7" align="center" style="background:#DCDCDC;" + |Congenital platelet disorders | ||
! align="center" style="background:#DCDCDC;" + |MYH-9 related disorders | ! align="center" style="background:#DCDCDC;" + |MYH-9 related disorders | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 181: | Line 246: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 193: | Line 260: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! | |||
! align="center" style="background:#DCDCDC;" + |Bernard-Soulier syndrome | ! align="center" style="background:#DCDCDC;" + |Bernard-Soulier syndrome | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 204: | Line 277: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 216: | Line 291: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! | |||
! align="center" style="background:#DCDCDC;" + |Gray platelet syndrome | ! align="center" style="background:#DCDCDC;" + |Gray platelet syndrome | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 227: | Line 308: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 239: | Line 322: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! | |||
! align="center" style="background:#DCDCDC;" + |Wiskott-Aldrich syndrome | ! align="center" style="background:#DCDCDC;" + |Wiskott-Aldrich syndrome | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 250: | Line 339: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 262: | Line 353: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! | |||
! align="center" style="background:#DCDCDC;" + |Thrombocytopenia with absent radius (TAR) syndrome | ! align="center" style="background:#DCDCDC;" + |Thrombocytopenia with absent radius (TAR) syndrome | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 273: | Line 370: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 285: | Line 384: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! | |||
! align="center" style="background:#DCDCDC;" + |Alport syndrome | ! align="center" style="background:#DCDCDC;" + |Alport syndrome | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 296: | Line 401: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 308: | Line 415: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! | |||
! align="center" style="background:#DCDCDC;" + |Von Willebrand disease | ! align="center" style="background:#DCDCDC;" + |Von Willebrand disease | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 319: | Line 432: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 333: | Line 448: | ||
! | ! | ||
! | ! | ||
! | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 343: | Line 464: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 355: | Line 478: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! | |||
! | ! | ||
! | ! | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 367: | Line 496: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 381: | Line 512: | ||
! | ! | ||
! | ! | ||
! | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 391: | Line 528: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 405: | Line 544: | ||
! | ! | ||
! | ! | ||
! | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 415: | Line 560: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 427: | Line 574: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! rowspan="7" |Infection-induced | |||
! rowspan="2" align="center" style="background:#DCDCDC;" + |Viral infections | ! rowspan="2" align="center" style="background:#DCDCDC;" + |Viral infections | ||
! align="center" style="background:#DCDCDC;" + |rubella, mumps, varicella, parvovirus, hepatitis C, and Epstein-Barr virus | ! align="center" style="background:#DCDCDC;" + |rubella, mumps, varicella, parvovirus, hepatitis C, and Epstein-Barr virus | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 440: | Line 593: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 457: | Line 612: | ||
* An ITP-like condition called primary HIV-associated thrombocytopenia (PHAT) | * An ITP-like condition called primary HIV-associated thrombocytopenia (PHAT) | ||
* Secondary opportunistic infections | * Secondary opportunistic infections | ||
! | |||
! | |||
! | |||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 466: | Line 626: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 481: | Line 643: | ||
! align="center" style="background:#DCDCDC;" + |Sepsis | ! align="center" style="background:#DCDCDC;" + |Sepsis | ||
!Direct bone marrow suppression | !Direct bone marrow suppression | ||
!+ | |||
! | |||
! | |||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 490: | Line 657: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 504: | Line 673: | ||
! align="center" style="background:#DCDCDC;" + |Helicobacter pylori | ! align="center" style="background:#DCDCDC;" + |Helicobacter pylori | ||
!Immune thrombocytopenia | !Immune thrombocytopenia | ||
! | |||
! | |||
! | |||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 513: | Line 687: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 526: | Line 702: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Leptospirosis, brucellosis, anaplasmosis, and other tick-borne infections | ! align="center" style="background:#DCDCDC;" + |Leptospirosis, brucellosis, anaplasmosis, and other tick-borne infections | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 536: | Line 717: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 550: | Line 733: | ||
! rowspan="2" align="center" style="background:#DCDCDC;" + |Intracellular parasites | ! rowspan="2" align="center" style="background:#DCDCDC;" + |Intracellular parasites | ||
! align="center" style="background:#DCDCDC;" + |Malaria | ! align="center" style="background:#DCDCDC;" + |Malaria | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 560: | Line 748: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 573: | Line 763: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Babesiosis | ! align="center" style="background:#DCDCDC;" + |Babesiosis | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 583: | Line 778: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 595: | Line 792: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! rowspan="6" | | ! rowspan="6" |Drug-induced | ||
! align="center" style="background:#DCDCDC;" + |Drug-induced immune thrombocytopenia | ! align="center" style="background:#DCDCDC;" + |Drug-induced immune thrombocytopenia | ||
! | ! | ||
Line 609: | Line 806: | ||
* Quinine | * Quinine | ||
|Occurrence of drug-dependent, platelet-reactive antibodies | |Occurrence of drug-dependent, platelet-reactive antibodies | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 618: | Line 820: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 632: | Line 836: | ||
!'''Heparin-induced thrombocytopenia''' | !'''Heparin-induced thrombocytopenia''' | ||
! | ! | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 642: | Line 851: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 656: | Line 867: | ||
!'''Cytotoxic chemotherapy''' | !'''Cytotoxic chemotherapy''' | ||
! | ! | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 666: | Line 882: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 681: | Line 899: | ||
! | ! | ||
|Predictable, dose-dependent myelosuppression | |Predictable, dose-dependent myelosuppression | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 690: | Line 913: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 704: | Line 929: | ||
!OTC agents | !OTC agents | ||
!Quinine-containing beverages | !Quinine-containing beverages | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 714: | Line 944: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 728: | Line 960: | ||
! align="center" style="background:#DCDCDC;" + |'''Alcohol''' | ! align="center" style="background:#DCDCDC;" + |'''Alcohol''' | ||
! | ! | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 738: | Line 975: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 753: | Line 992: | ||
!'''Malignancy''' | !'''Malignancy''' | ||
! | ! | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 763: | Line 1,007: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 779: | Line 1,025: | ||
!folate, vitamin B12, copper | !folate, vitamin B12, copper | ||
|an autoimmune mechanism | |an autoimmune mechanism | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + |Mild | | align="center" style="background:#F5F5F5;" + |Mild | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 788: | Line 1,039: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 803: | Line 1,056: | ||
! rowspan="3" |'''Thrombotic microangiopathy (TMA)''' | ! rowspan="3" |'''Thrombotic microangiopathy (TMA)''' | ||
!Thrombotic thrombocytopenic purpura (TTP) | !Thrombotic thrombocytopenic purpura (TTP) | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 813: | Line 1,071: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 827: | Line 1,087: | ||
! | ! | ||
!Hemolytic uremic syndrome (HUS) | !Hemolytic uremic syndrome (HUS) | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 837: | Line 1,102: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 851: | Line 1,118: | ||
! | ! | ||
!Drug-induced TMA (DITMA) | !Drug-induced TMA (DITMA) | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 861: | Line 1,133: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 875: | Line 1,149: | ||
! rowspan="4" |'''Bone marrow disorders''' | ! rowspan="4" |'''Bone marrow disorders''' | ||
!Myelodysplastic syndromes | !Myelodysplastic syndromes | ||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
Line 899: | Line 1,180: | ||
|- | |- | ||
!Aplastic anemia | !Aplastic anemia | ||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
Line 923: | Line 1,211: | ||
|- | |- | ||
!Acute leukemia | !Acute leukemia | ||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
Line 947: | Line 1,242: | ||
|- | |- | ||
!Paroxysmal nocturnal hemoglobinuria (PNH) | !Paroxysmal nocturnal hemoglobinuria (PNH) | ||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
Line 972: | Line 1,274: | ||
!'''Rheumatologic/autoimmune disorders''' | !'''Rheumatologic/autoimmune disorders''' | ||
!Systemic lupus erythematosus (SLE) | !Systemic lupus erythematosus (SLE) | ||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
Line 999: | Line 1,308: | ||
! | ! | ||
!autoantibody-mediated syndrome | !autoantibody-mediated syndrome | ||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
Line 1,024: | Line 1,340: | ||
! | ! | ||
!splenomegaly | !splenomegaly | ||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
Line 1,049: | Line 1,372: | ||
! | ! | ||
!platelet destruction | !platelet destruction | ||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
Line 1,073: | Line 1,403: | ||
! | ! | ||
!platelet destruction | !platelet destruction | ||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
Line 1,097: | Line 1,434: | ||
! | ! | ||
!platelet destruction | !platelet destruction | ||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
Line 1,122: | Line 1,466: | ||
! | ! | ||
!immune-mediated platelet destruction | !immune-mediated platelet destruction | ||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! |
Revision as of 20:40, 14 August 2018
Thrombocytopenia Differential Diagnosis
Differentiating the diseases that can cause thrombocytopenia:
Category | Condition | Mechanism | Age range | Clinical manifestations | Para−clinical findings | Gold standard | Associated findings | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Signs | |||||||||||||||||||||||||||||
Lab Findings | Imaging | |||||||||||||||||||||||||||||
Severity | Fever | Bleeding | BP | Splenomegaly | CBC | PBS | Bone marrow exam | |||||||||||||||||||||||
Myelosuppression | Platelet destruction in bloodstream | Platelet destruction in spleen/liver | History | Plt | HB | WBC | PT | PTT | BT | |||||||||||||||||||||
Gestational thrombocytopenia | ||||||||||||||||||||||||||||||
Chronic liver disease | ||||||||||||||||||||||||||||||
portal hypertension | ||||||||||||||||||||||||||||||
Hypersplenism | ||||||||||||||||||||||||||||||
Immune thrombocytopenia | Antibody-mediated platelet destruction | Moderate to severe | - | Diagnosis of exclusion | ||||||||||||||||||||||||||
Congenital platelet disorders | MYH-9 related disorders | |||||||||||||||||||||||||||||
Bernard-Soulier syndrome | ||||||||||||||||||||||||||||||
Gray platelet syndrome | ||||||||||||||||||||||||||||||
Wiskott-Aldrich syndrome | ||||||||||||||||||||||||||||||
Thrombocytopenia with absent radius (TAR) syndrome | ||||||||||||||||||||||||||||||
Alport syndrome | ||||||||||||||||||||||||||||||
Von Willebrand disease | ||||||||||||||||||||||||||||||
Infection-induced | Viral infections | rubella, mumps, varicella, parvovirus, hepatitis C, and Epstein-Barr virus | ||||||||||||||||||||||||||||
HIV |
|
|||||||||||||||||||||||||||||
Bacterial infections | Sepsis | Direct bone marrow suppression | + | |||||||||||||||||||||||||||
Helicobacter pylori | Immune thrombocytopenia | |||||||||||||||||||||||||||||
Leptospirosis, brucellosis, anaplasmosis, and other tick-borne infections | ||||||||||||||||||||||||||||||
Intracellular parasites | Malaria | |||||||||||||||||||||||||||||
Babesiosis | ||||||||||||||||||||||||||||||
Drug-induced | Drug-induced immune thrombocytopenia |
|
Occurrence of drug-dependent, platelet-reactive antibodies | |||||||||||||||||||||||||||
Heparin-induced thrombocytopenia | ||||||||||||||||||||||||||||||
Cytotoxic chemotherapy | ||||||||||||||||||||||||||||||
Radiation therapy | Predictable, dose-dependent myelosuppression | |||||||||||||||||||||||||||||
OTC agents | Quinine-containing beverages | |||||||||||||||||||||||||||||
Alcohol | ||||||||||||||||||||||||||||||
Malignancy | ||||||||||||||||||||||||||||||
Nutrient deficiencies | folate, vitamin B12, copper | an autoimmune mechanism | Mild | |||||||||||||||||||||||||||
Thrombotic microangiopathy (TMA) | Thrombotic thrombocytopenic purpura (TTP) | |||||||||||||||||||||||||||||
Hemolytic uremic syndrome (HUS) | ||||||||||||||||||||||||||||||
Drug-induced TMA (DITMA) | ||||||||||||||||||||||||||||||
Bone marrow disorders | Myelodysplastic syndromes | |||||||||||||||||||||||||||||
Aplastic anemia | ||||||||||||||||||||||||||||||
Acute leukemia | ||||||||||||||||||||||||||||||
Paroxysmal nocturnal hemoglobinuria (PNH) | ||||||||||||||||||||||||||||||
Rheumatologic/autoimmune disorders | Systemic lupus erythematosus (SLE) | |||||||||||||||||||||||||||||
Antiphospholipid syndrome (APS) | autoantibody-mediated syndrome | |||||||||||||||||||||||||||||
Felty's syndrome | splenomegaly | |||||||||||||||||||||||||||||
vascular | giant capillary hemangioma, | platelet destruction | ||||||||||||||||||||||||||||
large aortic aneurysms, | platelet destruction | |||||||||||||||||||||||||||||
cardiopulmonary bypass | platelet destruction | |||||||||||||||||||||||||||||
Post-transfusion purpura | immune-mediated platelet destruction |